Review




Structured Review

Proteintech tfrc
Tfrc, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 286 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/10084+2+ap/CD71+Antibody/pm41915328-180-15-16
Average 96 stars, based on 286 article reviews
tfrc - by Bioz Stars, 2026-09
96/100 stars

Images

Related Articles

other:

Article Title: Extracellular vesicle-based targeted protein degradation platform for multiple extracellular proteins
Article Snippet: CD71 Polyclonal antibody , Proteintech , 10084-2-AP.




Similar Products

96
Proteintech tfrc
Tfrc, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/10084+2+ap/CD71+Antibody/pm41915328-180-15-16
Average 96 stars, based on 1 article reviews
tfrc - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

96
Proteintech transferrin receptor
Transferrin Receptor, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/10084+2+ap/CD71+Antibody/pmc13009067-88-57-60
Average 96 stars, based on 1 article reviews
transferrin receptor - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

96
Proteintech transferrin receptor 1 tfr1
Transferrin Receptor 1 Tfr1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/10084+2+ap/CD71+Antibody/pm41812835-81-38-77
Average 96 stars, based on 1 article reviews
transferrin receptor 1 tfr1 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

96
Proteintech ncoa4
Ncoa4, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/10084+2+ap/CD71+Antibody/pm41797156-61-25-26
Average 96 stars, based on 1 article reviews
ncoa4 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

96
Proteintech cd71 antibody
Based on spytag and spycatcher, scfv targeting Claudin18.2 was covalently linked to heavy chain ferritin to form ferritin nanoparticle containing 24 anti-claudin18.2 scfv, which can be used for early targeting of the gastric cancer microenvironment by targeting <t>CD71</t> with claudin18.2, and the encapsulation of AIE enables multimodal diagnosis of early gastric cancer as well as photothermal therapy.
Cd71 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/10084+2+ap/CD71+Antibody/pmc12818144-228-6-21
Average 96 stars, based on 1 article reviews
cd71 antibody - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

96
Proteintech tfr 1 antibody
Based on spytag and spycatcher, scfv targeting Claudin18.2 was covalently linked to heavy chain ferritin to form ferritin nanoparticle containing 24 anti-claudin18.2 scfv, which can be used for early targeting of the gastric cancer microenvironment by targeting <t>CD71</t> with claudin18.2, and the encapsulation of AIE enables multimodal diagnosis of early gastric cancer as well as photothermal therapy.
Tfr 1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/10084+2+ap/CD71+Antibody/pm41616983-45-94-97
Average 96 stars, based on 1 article reviews
tfr 1 antibody - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

96
Proteintech anti dmt1
Based on spytag and spycatcher, scfv targeting Claudin18.2 was covalently linked to heavy chain ferritin to form ferritin nanoparticle containing 24 anti-claudin18.2 scfv, which can be used for early targeting of the gastric cancer microenvironment by targeting <t>CD71</t> with claudin18.2, and the encapsulation of AIE enables multimodal diagnosis of early gastric cancer as well as photothermal therapy.
Anti Dmt1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/10084+2+ap/CD71+Antibody/pm41581630-128-30-31
Average 96 stars, based on 1 article reviews
anti dmt1 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

96
Proteintech rabbit
Based on spytag and spycatcher, scfv targeting Claudin18.2 was covalently linked to heavy chain ferritin to form ferritin nanoparticle containing 24 anti-claudin18.2 scfv, which can be used for early targeting of the gastric cancer microenvironment by targeting <t>CD71</t> with claudin18.2, and the encapsulation of AIE enables multimodal diagnosis of early gastric cancer as well as photothermal therapy.
Rabbit, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/10084+2+ap/CD71+Antibody/pm41581630-128-26-28
Average 96 stars, based on 1 article reviews
rabbit - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

96
Proteintech cd71 polyclonal antibody
( A ) The uptake levels of specific antibody-blocking EVs (IgG, <t>CD71,</t> SQSTM1, TMEM59, CCN1, ITM2B, ITM2C) were detected after incubation for 12 h. IgG control was used to normalize the grayscale values of each group. Data were analyzed by one-way ANOVA ( n = 3). ( B ) The uptake levels of specific gene-knockdown EVs (Vector, CD71, SQSTM1, TMEM59, CCN1, ITM2B, ITM2C) were detected after incubation for 12 h. Vector control was used to normalize the grayscale values of each group. Data were analyzed by one-way ANOVA ( n = 3). ( C ) Control EVs and SQSTM1 KD EVs were incubated with NPCs for 12 h. Uptake level was analyzed at this time while degradation level was detected following wash out and another 12 h incubation ( n = 3). ( D ) IEM assay to detect the expression of SQSTM1 on HEK-293T derived EVs (scale bar: 100 nm). ( E ) Anti-SQSTM1 antibody was used to pull down HEK-293T derived EVs. IgG was used as negative control. SQSTM1 as well as EV marker-CD63 were detected by western blot. ( F ) Control or SQSTM1 KD EVs were added to NPCs and co-incubated for 12 h. Then, free EVs were wash out and replaced by free mediun containing 50 nM BafA1 for 12 h. After incubation, lysosome enrichment method was used to detect the sorting efficiency of control and SQSTM1 knockdown EVs into lysosomes in NPCs ( n = 3). ( G ) Control or SQSTM1 KD EVs were added to NPCs and co-incubated for 12 h. Then, free EVs were washed out and replaced by free mediun containing 50 nM BafA1 for 12 h. After incubation, immunofluorescence assay was used to detect the co-localization of EGFP with LampII (scale bar: 10 µm) ( n = 6); ( H ) Control or SQSTM1 KD EVs were added to HeLa cells and co-incubated for 12 h. Then, free EVs were washed out and replaced by free mediun containing 50 nM BafA1 for 12 h. After incubation, lysosome enrichment method was used to detect the sorting efficiency of control and SQSTM1 knockdown EVs into lysosomes in HeLa cells ( n = 3); ( I , J ) Analysis of degradation rate ( I ) and lysosomal sorting efficiency ( J ) of control and SQSTM1 overexpression EVs in NPCs ( n = 3); ( K , L ) Analysis of degradation rate ( K ) and lysosomal sorting efficiency (l) of control and SQSTM1 overexpression EVs in HeLa cells ( n = 3). Data were analyzed by one-way ANOVA ( A , B ) unpaired two-tailed t tests ( C , F , G , H , I , J , K , L ). Data were shown as mean ± SD. Each n in ( A , B , C , F , G , H , I , J , K , L ) is biological independent samples. The P values are labeled in the figure.
Cd71 Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/10084+2+ap/CD71+Antibody/pmc12905291-13-0-4
Average 96 stars, based on 1 article reviews
cd71 polyclonal antibody - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

Image Search Results


Based on spytag and spycatcher, scfv targeting Claudin18.2 was covalently linked to heavy chain ferritin to form ferritin nanoparticle containing 24 anti-claudin18.2 scfv, which can be used for early targeting of the gastric cancer microenvironment by targeting CD71 with claudin18.2, and the encapsulation of AIE enables multimodal diagnosis of early gastric cancer as well as photothermal therapy.

Journal: Materials Today Bio

Article Title: Ferritin-nanocaged aggregation-induced emission nanoaggregates for integrated sensitive detection and treatment of gastric cancer

doi: 10.1016/j.mtbio.2026.102769

Figure Lengend Snippet: Based on spytag and spycatcher, scfv targeting Claudin18.2 was covalently linked to heavy chain ferritin to form ferritin nanoparticle containing 24 anti-claudin18.2 scfv, which can be used for early targeting of the gastric cancer microenvironment by targeting CD71 with claudin18.2, and the encapsulation of AIE enables multimodal diagnosis of early gastric cancer as well as photothermal therapy.

Article Snippet: The Claudin18.2 antibody (Catalog number: 66167-1-Ig), CD71 antibody (Catalog number: 66180-1-Ig), and GAPDH antibody (Catalog number: 60004-1-Ig) were all purchased from Proteintech.

Techniques: Encapsulation, Biomarker Discovery

Validation of Claudin18.2 and TFRC(CD71) expression in gastric cancer patients. (A) Analysis of Claudin18 and TFRC expression in different cancer species based on TCGA database. (B–C) Analysis of Claudin18 and TFRC (CD71) molecules expression in gastric cancer patients with different stages based on TCGA database. (D) Analysis of Claudin18 and CD71 expression in tissues of gastric cancer patients based on immunohistochemical results from the Human protein atlas database. (E) Unsupervised clustering algorithm to analyze different cell subpopulations in single-cell data from GSEA gastric cancer patients. (F) Analysis of different cell subpopulations expressing Claudin18 and CD71 in gastric cancer patients.

Journal: Materials Today Bio

Article Title: Ferritin-nanocaged aggregation-induced emission nanoaggregates for integrated sensitive detection and treatment of gastric cancer

doi: 10.1016/j.mtbio.2026.102769

Figure Lengend Snippet: Validation of Claudin18.2 and TFRC(CD71) expression in gastric cancer patients. (A) Analysis of Claudin18 and TFRC expression in different cancer species based on TCGA database. (B–C) Analysis of Claudin18 and TFRC (CD71) molecules expression in gastric cancer patients with different stages based on TCGA database. (D) Analysis of Claudin18 and CD71 expression in tissues of gastric cancer patients based on immunohistochemical results from the Human protein atlas database. (E) Unsupervised clustering algorithm to analyze different cell subpopulations in single-cell data from GSEA gastric cancer patients. (F) Analysis of different cell subpopulations expressing Claudin18 and CD71 in gastric cancer patients.

Article Snippet: The Claudin18.2 antibody (Catalog number: 66167-1-Ig), CD71 antibody (Catalog number: 66180-1-Ig), and GAPDH antibody (Catalog number: 60004-1-Ig) were all purchased from Proteintech.

Techniques: Biomarker Discovery, Expressing, Immunohistochemical staining

Characterisation of the targeting of AIE@HFn-scfv to different tumor cells in vitro and its killing properties in combination with laser-induced tumor cells apoptosis. (A) Western blotting identifies the expression of CD71 and claudin18.2 in different cells. (B) Confocal imaging identifies that AIE@HFn-scfv-FITC targets gastric cancer cell line MGC803 mainly through CD71 with Claudin18.2 (0.1 mg/mL, based on fusion protein concentration) in culture medium. Scale bar: 20 μm. (C) Flow cytometry statistics of HFn-Sc-FITC uptake by different cells (0.1 mg/mL, based on fusion protein concentration) in culture medium. (D) Flow cytometry statistics of St-scfv-FITC uptake by different cells (0.1 mg/mL, based on fusion protein concentration) in culture medium. (E) Flow cytometry statistics of HFn-scfv-FITC uptake by different cells. (F) Flow cytometry statistics of HFn-scfv-FITC and St-scfv-FITC uptake by MGC803, HEK239-1 and HEK293-2 (0.1 mg/mL, based on fusion protein concentration) in culture medium. (G) CCK8 assay to detect the inhibitory properties of cell proliferation in different indicated treatment groups (0.8 W/cm 2 , 808 nm, 5 min). (H) Crystalline violet staining to assess the characteristics of MGC803 tumor cell killing by different indicated treatment groups (0.1 mg/mL, based on fusion protein concentration) in culture medium (0.8 W/cm 2 , 808 nm, 5 min). (I) Crystalline violet staining identifies a positive correlation between AIE@HFn-scfv and laser power (0.1 mg/mL, based on fusion protein concentration) in culture medium (0.8 W/cm 2 , 808 nm, 5 min). Statistical analysis was performed using one-way ANOVA with Tukey's multiple comparison test. Data are presented as the mean ± SEM. ∗P < 0.05,∗∗P < 0.01, ∗∗∗P < 0.001, and NS: not significant. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Journal: Materials Today Bio

Article Title: Ferritin-nanocaged aggregation-induced emission nanoaggregates for integrated sensitive detection and treatment of gastric cancer

doi: 10.1016/j.mtbio.2026.102769

Figure Lengend Snippet: Characterisation of the targeting of AIE@HFn-scfv to different tumor cells in vitro and its killing properties in combination with laser-induced tumor cells apoptosis. (A) Western blotting identifies the expression of CD71 and claudin18.2 in different cells. (B) Confocal imaging identifies that AIE@HFn-scfv-FITC targets gastric cancer cell line MGC803 mainly through CD71 with Claudin18.2 (0.1 mg/mL, based on fusion protein concentration) in culture medium. Scale bar: 20 μm. (C) Flow cytometry statistics of HFn-Sc-FITC uptake by different cells (0.1 mg/mL, based on fusion protein concentration) in culture medium. (D) Flow cytometry statistics of St-scfv-FITC uptake by different cells (0.1 mg/mL, based on fusion protein concentration) in culture medium. (E) Flow cytometry statistics of HFn-scfv-FITC uptake by different cells. (F) Flow cytometry statistics of HFn-scfv-FITC and St-scfv-FITC uptake by MGC803, HEK239-1 and HEK293-2 (0.1 mg/mL, based on fusion protein concentration) in culture medium. (G) CCK8 assay to detect the inhibitory properties of cell proliferation in different indicated treatment groups (0.8 W/cm 2 , 808 nm, 5 min). (H) Crystalline violet staining to assess the characteristics of MGC803 tumor cell killing by different indicated treatment groups (0.1 mg/mL, based on fusion protein concentration) in culture medium (0.8 W/cm 2 , 808 nm, 5 min). (I) Crystalline violet staining identifies a positive correlation between AIE@HFn-scfv and laser power (0.1 mg/mL, based on fusion protein concentration) in culture medium (0.8 W/cm 2 , 808 nm, 5 min). Statistical analysis was performed using one-way ANOVA with Tukey's multiple comparison test. Data are presented as the mean ± SEM. ∗P < 0.05,∗∗P < 0.01, ∗∗∗P < 0.001, and NS: not significant. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: The Claudin18.2 antibody (Catalog number: 66167-1-Ig), CD71 antibody (Catalog number: 66180-1-Ig), and GAPDH antibody (Catalog number: 60004-1-Ig) were all purchased from Proteintech.

Techniques: In Vitro, Western Blot, Expressing, Imaging, Protein Concentration, Flow Cytometry, CCK-8 Assay, Staining, Comparison

( A ) The uptake levels of specific antibody-blocking EVs (IgG, CD71, SQSTM1, TMEM59, CCN1, ITM2B, ITM2C) were detected after incubation for 12 h. IgG control was used to normalize the grayscale values of each group. Data were analyzed by one-way ANOVA ( n = 3). ( B ) The uptake levels of specific gene-knockdown EVs (Vector, CD71, SQSTM1, TMEM59, CCN1, ITM2B, ITM2C) were detected after incubation for 12 h. Vector control was used to normalize the grayscale values of each group. Data were analyzed by one-way ANOVA ( n = 3). ( C ) Control EVs and SQSTM1 KD EVs were incubated with NPCs for 12 h. Uptake level was analyzed at this time while degradation level was detected following wash out and another 12 h incubation ( n = 3). ( D ) IEM assay to detect the expression of SQSTM1 on HEK-293T derived EVs (scale bar: 100 nm). ( E ) Anti-SQSTM1 antibody was used to pull down HEK-293T derived EVs. IgG was used as negative control. SQSTM1 as well as EV marker-CD63 were detected by western blot. ( F ) Control or SQSTM1 KD EVs were added to NPCs and co-incubated for 12 h. Then, free EVs were wash out and replaced by free mediun containing 50 nM BafA1 for 12 h. After incubation, lysosome enrichment method was used to detect the sorting efficiency of control and SQSTM1 knockdown EVs into lysosomes in NPCs ( n = 3). ( G ) Control or SQSTM1 KD EVs were added to NPCs and co-incubated for 12 h. Then, free EVs were washed out and replaced by free mediun containing 50 nM BafA1 for 12 h. After incubation, immunofluorescence assay was used to detect the co-localization of EGFP with LampII (scale bar: 10 µm) ( n = 6); ( H ) Control or SQSTM1 KD EVs were added to HeLa cells and co-incubated for 12 h. Then, free EVs were washed out and replaced by free mediun containing 50 nM BafA1 for 12 h. After incubation, lysosome enrichment method was used to detect the sorting efficiency of control and SQSTM1 knockdown EVs into lysosomes in HeLa cells ( n = 3); ( I , J ) Analysis of degradation rate ( I ) and lysosomal sorting efficiency ( J ) of control and SQSTM1 overexpression EVs in NPCs ( n = 3); ( K , L ) Analysis of degradation rate ( K ) and lysosomal sorting efficiency (l) of control and SQSTM1 overexpression EVs in HeLa cells ( n = 3). Data were analyzed by one-way ANOVA ( A , B ) unpaired two-tailed t tests ( C , F , G , H , I , J , K , L ). Data were shown as mean ± SD. Each n in ( A , B , C , F , G , H , I , J , K , L ) is biological independent samples. The P values are labeled in the figure.

Journal: EMBO Molecular Medicine

Article Title: Extracellular vesicle-based targeted protein degradation platform for multiple extracellular proteins

doi: 10.1038/s44321-025-00371-8

Figure Lengend Snippet: ( A ) The uptake levels of specific antibody-blocking EVs (IgG, CD71, SQSTM1, TMEM59, CCN1, ITM2B, ITM2C) were detected after incubation for 12 h. IgG control was used to normalize the grayscale values of each group. Data were analyzed by one-way ANOVA ( n = 3). ( B ) The uptake levels of specific gene-knockdown EVs (Vector, CD71, SQSTM1, TMEM59, CCN1, ITM2B, ITM2C) were detected after incubation for 12 h. Vector control was used to normalize the grayscale values of each group. Data were analyzed by one-way ANOVA ( n = 3). ( C ) Control EVs and SQSTM1 KD EVs were incubated with NPCs for 12 h. Uptake level was analyzed at this time while degradation level was detected following wash out and another 12 h incubation ( n = 3). ( D ) IEM assay to detect the expression of SQSTM1 on HEK-293T derived EVs (scale bar: 100 nm). ( E ) Anti-SQSTM1 antibody was used to pull down HEK-293T derived EVs. IgG was used as negative control. SQSTM1 as well as EV marker-CD63 were detected by western blot. ( F ) Control or SQSTM1 KD EVs were added to NPCs and co-incubated for 12 h. Then, free EVs were wash out and replaced by free mediun containing 50 nM BafA1 for 12 h. After incubation, lysosome enrichment method was used to detect the sorting efficiency of control and SQSTM1 knockdown EVs into lysosomes in NPCs ( n = 3). ( G ) Control or SQSTM1 KD EVs were added to NPCs and co-incubated for 12 h. Then, free EVs were washed out and replaced by free mediun containing 50 nM BafA1 for 12 h. After incubation, immunofluorescence assay was used to detect the co-localization of EGFP with LampII (scale bar: 10 µm) ( n = 6); ( H ) Control or SQSTM1 KD EVs were added to HeLa cells and co-incubated for 12 h. Then, free EVs were washed out and replaced by free mediun containing 50 nM BafA1 for 12 h. After incubation, lysosome enrichment method was used to detect the sorting efficiency of control and SQSTM1 knockdown EVs into lysosomes in HeLa cells ( n = 3); ( I , J ) Analysis of degradation rate ( I ) and lysosomal sorting efficiency ( J ) of control and SQSTM1 overexpression EVs in NPCs ( n = 3); ( K , L ) Analysis of degradation rate ( K ) and lysosomal sorting efficiency (l) of control and SQSTM1 overexpression EVs in HeLa cells ( n = 3). Data were analyzed by one-way ANOVA ( A , B ) unpaired two-tailed t tests ( C , F , G , H , I , J , K , L ). Data were shown as mean ± SD. Each n in ( A , B , C , F , G , H , I , J , K , L ) is biological independent samples. The P values are labeled in the figure.

Article Snippet: CD71 Polyclonal antibody , Proteintech , 10084-2-AP.

Techniques: Blocking Assay, Incubation, Control, Knockdown, Plasmid Preparation, Expressing, Derivative Assay, Negative Control, Marker, Western Blot, Immunofluorescence, Over Expression, Two Tailed Test, Labeling